
Interview with Peter Sallstig, MD, MBA
Santen’s legacy, global products, NA product portfolio, clinical trials and more.Peter also dives into the disease state of vernal keratoconjunctivitis (VKC) and the recent US launch of Verkazia®, the first and only topical immunomodulator approved for the treatment of VKC in children and adults